Rocket Pharmaceuticals Advances RP-A501 Toward Danon Disease Approval
CRANBURY, N.J. — September 15, 2026 Rocket Pharmaceuticals, Inc. announced alignment with the U.S. Food and Drug Administration (FDA)...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CRANBURY, N.J. — September 15, 2026 Rocket Pharmaceuticals, Inc. announced alignment with the U.S. Food and Drug Administration (FDA)...
LAUSANNE, Switzerland, September 2, 2026 NewBiologix S.A. has entered into an agreement with Synastra Biotechnology Inc. to develop a...
Novato, California, August 19, 2026 Ultragenyx Pharmaceutical Inc. has announced that the U.S. Food and Drug Administration (FDA) granted...
COLUMBUS, Ohio, May 13, 2026 Andelyn Biosciences announced that it has received full certification under the Initiative for Certification...
MIAMI, Fla., December 17, 2025 — Veru Inc., a late-stage biopharmaceutical company, reported its fiscal year 2025 financial results...
CAMBRIDGE, Massachusetts, December 17, 2025 — uBriGene, a leader in advanced biopharmaceutical manufacturing, has launched LVV Turbo™, its next-generation...
